Advanced BioMedical Technologies Inc.

OTC: ABMT · Healthcare · Medical - Devices

PublicHQ New York, NY · New YorkCIK 0001385799Reports USD

#1030 of 1,418 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ 10GM —SS 42

v0.1 · 25/100 weight · pillars only

↑ revenue growth (YoY), listing tenure · ↓ disclosure history, filing timeliness

Methodology →

Revenue TTM

$400.1k

Rev growth YoY (TTM)

+264.3%

Net income (FY)

-$672.0k

Employees

as of 2026-08-28

Market cap

$50.0k

as of 2026-08-28

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$123.6k$123.6k2020

Net income-$672.0k-$672.0k2020

Operating income-$446.6k-$446.6k2020

Total assets$469.2k$469.2k2020

Equity-$7.4M-$7.4M2020

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Advanced BioMedical Technologies Inc.’s revenue?

Advanced BioMedical Technologies Inc. booked $123.6k in FY2020 revenue, growing 960% year over year — faster than 96% of Healthcare companies we track, at a -543.7% net margin.

Peers · Healthcare

Panamera Holdings Corporation31D Candel Therapeutics, Inc.33D Ainos, Inc.41D AI/ML Innovations Inc.——Viracta Therapeutics, Inc.——Soligenix, Inc.42D

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOHui Wang

SectorHealthcare

IndustryMedical - Devices

HeadquartersNew York, NY

ExchangeOTC: ABMT

Employees17

IPO date2008-02-21

Latest filings

10-Q2021-09-13 10-Q2021-06-21 10-Q2021-03-22 10-K2021-01-29 10-Q2020-09-21 10-Q2020-06-22 10-Q2020-04-30 10-K2020-03-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.